Human Kallikrein 7/KLK7 Protein (active form)

Cat. No. KLK-HM007

Description

Source	Recombinant Human Kallikrein 7/KLK7 Protein is expressed from HEK293 without tag.
	It contains Ile30-Arg253.
Accession	P49862
Molecular Weight	The protein has a predicted MW of 24.44 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.1 EU per μg by the LAL method.
Purity	> 90% as determined by Bis-Tris PAGE
	> 90% as determined by HPLC

Formulation and Storage

Formulation	Supplied as 0.22 μm filtered solution in 20mM HEPES, 150mM NaCl (pH 7.5).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kallikrein 7 (KLK7) is a secreted serine protease with chymotrypsic protease activity. Abnormally high expression of KLK7 is closely related to the occurrence and development of various types of cancer. Therefore, KLK7 has been identified as a potential target for cancer drug development design in recent years. KLK7 mediates various biological and pathological processes in tumorigenesis, including cell proliferation, migration, invasion, angiogenesis, and cell metabolism, by hydrolyzing a series of substrates such as membrane proteins, extracellular matrix proteins, and cytokines.

Assay Data

Bis-Tris PAGE



Human Kallikrein 7 on Bis-Tris PAGE under reduced condition. The purity is greater than 90%.

SEC-HPLC

Human Kallikrein 7/KLK7 Protein (active form)

Cat. No. KLK-HM007

Assay Data



The purity of Human Kallikrein 7 is greater than 90% as determined by SEC-HPLC.

Bioactivity Data

Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2. The specific activity is >150 pmol/min/μg.